Q5125 Filgrastim - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Filgrastim

Brand Name:

Releuko

Strength:

1mcg

HCPCS:

Q5125

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Immunostimulant

Minor Drug Class:

Granulocyte colony stimulating factor

Oral (Y/N):

No

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

Sept. 27, 2022

CMS Discontinuation Date:

Status:

In Use